Atlas Trials

Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

Clinical trial NCT02715284 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT02715284
Sponsor
Tesaro, Inc.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Neoplasms
Start date
2016-03-07
Primary completion
2026-05-18
Enrollment
730

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.